Search Results 1051-1060 of 21691 for Inhibition

1. Nalbuphine (injection route) - Side effects & uses - Mayo Clinic

   Do not use this medicine if you are using or have used an MAO inhibitor (eg, Eldepryl®, Marplan®, Nardil®, or Parnate®) within the past 14 days. This ...

2. Liver Tumor Ablation Clinical Trials - Mayo Clinic Research

   The purpose of this study is to test the validity of durvalumab and VEGF inhibitor therapy to enhance anti-tumor immune responses to produce significant and ...

3. Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) - Mayo Clinic

   Subjects previously treated with anagrelide or JAK inhibitors. Inadequate liver function at screening and Day 1 (before drug administration) as demonstrated ...

4. Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer - Mayo Clinic

   Participation eligibility · Prior anti-cancer treatment for metastatic colorectal cancer · Prior exposure to PARP (poly ADP-ribose polymerase) inhibitors · The ...

5. A Study Of The Effect Of IW-1973 On The Exercise Capacity Of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) - Mayo Clinic

   Patient is taking specific inhibitors of phosphodiesterase 5 (PDE5), nonspecific inhibitors of PDE5, any supplements for the treatment of erectile ...

6. Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim 3) - Mayo Clinic

   About this study. To determine the effect of 12 weeks of chronic PDEV inhibition with Tadalafil versus placebo on basal cardiorenal and humoral function and ...

7. Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) - Mayo Clinic

   Has received prior therapy with an immune checkpoint inhibitor (e.g., anti-programmed cell death [PD]-1, anti-PD ligand 1 [L1], anti-PD-L2 agent, or anti ...

8. Hodgkin Clinical Trials - Mayo Clinic Research

   ... Inhibitor, in patients with relapsed/refractory Non-Hodgkin's lymphomas or advanced solid tumors. Study of Veltuzumab and 90Y-Epratuzumab in Relapsed ...

9. Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer - Mayo Clinic

   Any previous treatment with a PARP inhibitor, including olaparib and/or ... Concomitant use of known potent CYP3A4 inhibitors such as ketoconazole ...

10. Rafael Fonseca, M.D. - Doctors and Medical Staff - Mayo Clinic

    Advisory Board MemberEndeavor - Proteasome Inhibition Global Advisory Board. 2014 - 2015. MemberScientific Subcommittee on Plasma Cell Neoplasms, American ...